Myriad遗传学报告Q4收入令人失望,面临Q1损失,并宣布新的CEOSam Raha。 Myriad Genetics reports disappointing Q4 earnings, faces Q1 loss, and announces a new CEO, Sam Raha.

Myriad遗传学报告,尽管收入增加,但Q4收入低于预期,导致其股票价格下跌。 Myriad Genetics reported lower-than-expected Q4 earnings, despite revenue growth, leading to a drop in its stock price. 该公司预期在问题1中损失,但维持2025年财政预测。 The company expects a loss in Q1 but maintains its forecast for fiscal 2025. Myriad还宣布了领导层的改变,Sam Raha定于4月30日成为新的首席执行官,取代Paul Diaz。 Myriad also announced leadership changes, with Sam Raha set to become the new CEO on April 30, replacing Paul Diaz. 该公司以基因测试和精密医学闻名,市场上限为10.4亿美元,并面临各种分析师的评级。 The company, known for genetic testing and precision medicine, has a market cap of $1.04 billion and faces mixed analyst ratings.